Table 3 Open in new tab Univariate...

Characteristics	OR (95% CI)	P	OR (95% CI)	P
Age	1.01 (0.97–1.06)	0.550	1.03 (0.97–1.08)	0.282
Male	0.69 (0.33–1.48)	0.351	1.27 (0.61–2.64)	0.520
CKD	1.12 (0.49–2.57)	0.790	0.67 (0.31–1.47)	0.319
PM/ICD	0.63 (0.25–1.58)	0.327	1.93 (0.90–4.16)	0.093
Diuretic therapy increase at 2-month			0.81 (0.29–2.24)	0.681
Diuretic therapy reduction at 2-month			1.50 (0.68–3.35)	0.317
Beta-blocker therapy	1.10 (0.44–2.77)	0.840	0.51 (0.22–1.23)	0.134
Anti-RAAS therapy	0.84 (0.41–1.72)	0.642	0.52 (0.25–1.08)	0.081
MRA therapy	1.28 (0.63–2.59)	0.494	1.99 (0.95–4.18)	0.068
T-TEER	0.25 (0.12–0.52)	<0.001	0.47 (0.20–1.08)	0.076
Annuloplasty	2.90 (1.20–7.50)	0.020	1.40 (0.39–5.06)	0.608
Orthotopic replacement	3.39 (0.87–13.20)	0.077
Heterotopic replacement	5.28 (1.50–18.5)	0.009	8.65 (2.05–36.4)	0.003
Acute procedural success	0.63 (0.27–1.47)	0.289	0.59 (0.23–1.46)	0.256
TR reduction to at least moderate degree	0.48 (0.23–0.99)	0.049	0.60 (0.28–1.31)	0.202
Baseline LVEDD	0.98 (0.94–1.02)	0.369	0.99 (0.95–1.03)	0.833
Baseline LVEDD > 60 mm	1.12 (0.32–3.94)	0.864	0.58 (0.13–2.59)	0.476
Pre-discharge LVEDD	0.98 (0.94–1.03)	0.594	0.96 (0.92–1.01)	0.127
Delta LVEDD	1.01 (0.96–1.06)	0.687	0.96 (0.91–1.01)	0.135
Baseline LVEF	0.99 (0.96–1.02)	0.809	1.00 (0.97–1.04)	0.874
Baseline LVEF < 30%	2.47 (0.87–7.06)	0.089	0.89 (0.20–4.05)	0.882
Delta LVEF	0.97 (0.92–1.03)	0.337	0.99 (0.94–1.06)	0.882
Pre-discharge LVEF	0.98 (0.96–1.02)	0.385	0.99 (0.97–1.03)	0.986
Baseline TAPSE	0.98 (0.95–1.12)	0.411	1.00 (0.95–1.06)	0.400
Baseline TAPSE < 17 mm	1.41 (0.59–3.40)	0.433	1.17 (0.42–3.28)	0.754
TAPSE/sPAP	1.00 (0.98–1.02)	0.833	1.01 (0.99–1.02)	0.220
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.65–3.21)	0.356	0.90 (0.39–2.09)	0.824
Pre-discharge TAPSE	0.97 (0.88–1.08)	0.636	0.96 (0.85–1.07)	0.466
Atrial fibrillation	1.34 (0.65–2.77)	0.427	1.07 (0.51–2.22)	0.856

Characteristics

OR (95% CI)

Pre-discharge (n = 34)

2-month follow-up (n = 33)

Age

1.01 (0.97–1.06)

0.550

1.03 (0.97–1.08)

0.282

Male

0.69 (0.33–1.48)

0.351

1.27 (0.61–2.64)

0.520

CKD

1.12 (0.49–2.57)

0.790

0.67 (0.31–1.47)

0.319

PM/ICD

0.63 (0.25–1.58)

0.327

1.93 (0.90–4.16)

0.093

Diuretic therapy increase at 2-month

0.81 (0.29–2.24)

0.681

Diuretic therapy reduction at 2-month

1.50 (0.68–3.35)

0.317

Beta-blocker therapy

1.10 (0.44–2.77)

0.840

0.51 (0.22–1.23)

0.134

Anti-RAAS therapy

0.84 (0.41–1.72)

0.642

0.52 (0.25–1.08)

0.081

MRA therapy

1.28 (0.63–2.59)

0.494

1.99 (0.95–4.18)

0.068

T-TEER

0.25 (0.12–0.52)

<0.001

0.47 (0.20–1.08)

0.076

Annuloplasty

2.90 (1.20–7.50)

0.020

1.40 (0.39–5.06)

0.608

Orthotopic replacement

3.39 (0.87–13.20)

0.077

Heterotopic replacement

5.28 (1.50–18.5)

0.009

8.65 (2.05–36.4)

0.003

Acute procedural success

0.63 (0.27–1.47)

0.289

0.59 (0.23–1.46)

0.256

TR reduction to at least moderate degree

0.48 (0.23–0.99)

0.049

0.60 (0.28–1.31)

0.202

Baseline LVEDD

0.98 (0.94–1.02)

0.369

0.99 (0.95–1.03)

0.833

Baseline LVEDD > 60 mm

1.12 (0.32–3.94)

0.864

0.58 (0.13–2.59)

0.476

Pre-discharge LVEDD

0.98 (0.94–1.03)

0.594

0.96 (0.92–1.01)

0.127

Delta LVEDD

1.01 (0.96–1.06)

0.687

0.96 (0.91–1.01)

0.135

Baseline LVEF

0.99 (0.96–1.02)

0.809

1.00 (0.97–1.04)

0.874

Baseline LVEF < 30%

2.47 (0.87–7.06)

0.089

0.89 (0.20–4.05)

0.882

Delta LVEF

0.97 (0.92–1.03)

0.337

0.99 (0.94–1.06)

0.882

Pre-discharge LVEF

0.98 (0.96–1.02)

0.385

0.99 (0.97–1.03)

0.986

Baseline TAPSE

0.98 (0.95–1.12)

0.411

1.00 (0.95–1.06)

0.400

Baseline TAPSE < 17 mm

1.41 (0.59–3.40)

0.433

1.17 (0.42–3.28)

0.754

TAPSE/sPAP

1.00 (0.98–1.02)

0.833

1.01 (0.99–1.02)

0.220

Baseline RV impairment (TAPSE/sPAP < 0.406)

1.45 (0.65–3.21)

0.356

0.90 (0.39–2.09)

0.824

Pre-discharge TAPSE

0.97 (0.88–1.08)

0.636

0.96 (0.85–1.07)

0.466

Atrial fibrillation

1.34 (0.65–2.77)

0.427

1.07 (0.51–2.22)

0.856

Characteristics	OR (95% CI)	P	OR (95% CI)	P
Age	1.01 (0.97–1.06)	0.550	1.03 (0.97–1.08)	0.282
Male	0.69 (0.33–1.48)	0.351	1.27 (0.61–2.64)	0.520
CKD	1.12 (0.49–2.57)	0.790	0.67 (0.31–1.47)	0.319
PM/ICD	0.63 (0.25–1.58)	0.327	1.93 (0.90–4.16)	0.093
Diuretic therapy increase at 2-month			0.81 (0.29–2.24)	0.681
Diuretic therapy reduction at 2-month			1.50 (0.68–3.35)	0.317
Beta-blocker therapy	1.10 (0.44–2.77)	0.840	0.51 (0.22–1.23)	0.134
Anti-RAAS therapy	0.84 (0.41–1.72)	0.642	0.52 (0.25–1.08)	0.081
MRA therapy	1.28 (0.63–2.59)	0.494	1.99 (0.95–4.18)	0.068
T-TEER	0.25 (0.12–0.52)	<0.001	0.47 (0.20–1.08)	0.076
Annuloplasty	2.90 (1.20–7.50)	0.020	1.40 (0.39–5.06)	0.608
Orthotopic replacement	3.39 (0.87–13.20)	0.077
Heterotopic replacement	5.28 (1.50–18.5)	0.009	8.65 (2.05–36.4)	0.003
Acute procedural success	0.63 (0.27–1.47)	0.289	0.59 (0.23–1.46)	0.256
TR reduction to at least moderate degree	0.48 (0.23–0.99)	0.049	0.60 (0.28–1.31)	0.202
Baseline LVEDD	0.98 (0.94–1.02)	0.369	0.99 (0.95–1.03)	0.833
Baseline LVEDD > 60 mm	1.12 (0.32–3.94)	0.864	0.58 (0.13–2.59)	0.476
Pre-discharge LVEDD	0.98 (0.94–1.03)	0.594	0.96 (0.92–1.01)	0.127
Delta LVEDD	1.01 (0.96–1.06)	0.687	0.96 (0.91–1.01)	0.135
Baseline LVEF	0.99 (0.96–1.02)	0.809	1.00 (0.97–1.04)	0.874
Baseline LVEF < 30%	2.47 (0.87–7.06)	0.089	0.89 (0.20–4.05)	0.882
Delta LVEF	0.97 (0.92–1.03)	0.337	0.99 (0.94–1.06)	0.882
Pre-discharge LVEF	0.98 (0.96–1.02)	0.385	0.99 (0.97–1.03)	0.986
Baseline TAPSE	0.98 (0.95–1.12)	0.411	1.00 (0.95–1.06)	0.400
Baseline TAPSE < 17 mm	1.41 (0.59–3.40)	0.433	1.17 (0.42–3.28)	0.754
TAPSE/sPAP	1.00 (0.98–1.02)	0.833	1.01 (0.99–1.02)	0.220
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.65–3.21)	0.356	0.90 (0.39–2.09)	0.824
Pre-discharge TAPSE	0.97 (0.88–1.08)	0.636	0.96 (0.85–1.07)	0.466
Atrial fibrillation	1.34 (0.65–2.77)	0.427	1.07 (0.51–2.22)	0.856

Table 3

Open in new tab

Univariate analyses for MR worsening at both pre-discharge and 2-month echocardiographic assessment

Characteristics	OR (95% CI)	P	OR (95% CI)	P
	Pre-discharge (n = 34)		2-month follow-up (n = 33)
Age	1.01 (0.97–1.06)	0.550	1.03 (0.97–1.08)	0.282
Male	0.69 (0.33–1.48)	0.351	1.27 (0.61–2.64)	0.520
CKD	1.12 (0.49–2.57)	0.790	0.67 (0.31–1.47)	0.319
PM/ICD	0.63 (0.25–1.58)	0.327	1.93 (0.90–4.16)	0.093
Diuretic therapy increase at 2-month			0.81 (0.29–2.24)	0.681
Diuretic therapy reduction at 2-month			1.50 (0.68–3.35)	0.317
Beta-blocker therapy	1.10 (0.44–2.77)	0.840	0.51 (0.22–1.23)	0.134
Anti-RAAS therapy	0.84 (0.41–1.72)	0.642	0.52 (0.25–1.08)	0.081
MRA therapy	1.28 (0.63–2.59)	0.494	1.99 (0.95–4.18)	0.068
T-TEER	0.25 (0.12–0.52)	<0.001	0.47 (0.20–1.08)	0.076
Annuloplasty	2.90 (1.20–7.50)	0.020	1.40 (0.39–5.06)	0.608
Orthotopic replacement	3.39 (0.87–13.20)	0.077
Heterotopic replacement	5.28 (1.50–18.5)	0.009	8.65 (2.05–36.4)	0.003
Acute procedural success	0.63 (0.27–1.47)	0.289	0.59 (0.23–1.46)	0.256
TR reduction to at least moderate degree	0.48 (0.23–0.99)	0.049	0.60 (0.28–1.31)	0.202
Baseline LVEDD	0.98 (0.94–1.02)	0.369	0.99 (0.95–1.03)	0.833
Baseline LVEDD > 60 mm	1.12 (0.32–3.94)	0.864	0.58 (0.13–2.59)	0.476
Pre-discharge LVEDD	0.98 (0.94–1.03)	0.594	0.96 (0.92–1.01)	0.127
Delta LVEDD	1.01 (0.96–1.06)	0.687	0.96 (0.91–1.01)	0.135
Baseline LVEF	0.99 (0.96–1.02)	0.809	1.00 (0.97–1.04)	0.874
Baseline LVEF < 30%	2.47 (0.87–7.06)	0.089	0.89 (0.20–4.05)	0.882
Delta LVEF	0.97 (0.92–1.03)	0.337	0.99 (0.94–1.06)	0.882
Pre-discharge LVEF	0.98 (0.96–1.02)	0.385	0.99 (0.97–1.03)	0.986
Baseline TAPSE	0.98 (0.95–1.12)	0.411	1.00 (0.95–1.06)	0.400
Baseline TAPSE < 17 mm	1.41 (0.59–3.40)	0.433	1.17 (0.42–3.28)	0.754
TAPSE/sPAP	1.00 (0.98–1.02)	0.833	1.01 (0.99–1.02)	0.220
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.65–3.21)	0.356	0.90 (0.39–2.09)	0.824
Pre-discharge TAPSE	0.97 (0.88–1.08)	0.636	0.96 (0.85–1.07)	0.466
Atrial fibrillation	1.34 (0.65–2.77)	0.427	1.07 (0.51–2.22)	0.856

Characteristics	OR (95% CI)	P	OR (95% CI)	P
	Pre-discharge (n = 34)		2-month follow-up (n = 33)
Age	1.01 (0.97–1.06)	0.550	1.03 (0.97–1.08)	0.282
Male	0.69 (0.33–1.48)	0.351	1.27 (0.61–2.64)	0.520
CKD	1.12 (0.49–2.57)	0.790	0.67 (0.31–1.47)	0.319
PM/ICD	0.63 (0.25–1.58)	0.327	1.93 (0.90–4.16)	0.093
Diuretic therapy increase at 2-month			0.81 (0.29–2.24)	0.681
Diuretic therapy reduction at 2-month			1.50 (0.68–3.35)	0.317
Beta-blocker therapy	1.10 (0.44–2.77)	0.840	0.51 (0.22–1.23)	0.134
Anti-RAAS therapy	0.84 (0.41–1.72)	0.642	0.52 (0.25–1.08)	0.081
MRA therapy	1.28 (0.63–2.59)	0.494	1.99 (0.95–4.18)	0.068
T-TEER	0.25 (0.12–0.52)	<0.001	0.47 (0.20–1.08)	0.076
Annuloplasty	2.90 (1.20–7.50)	0.020	1.40 (0.39–5.06)	0.608
Orthotopic replacement	3.39 (0.87–13.20)	0.077
Heterotopic replacement	5.28 (1.50–18.5)	0.009	8.65 (2.05–36.4)	0.003
Acute procedural success	0.63 (0.27–1.47)	0.289	0.59 (0.23–1.46)	0.256
TR reduction to at least moderate degree	0.48 (0.23–0.99)	0.049	0.60 (0.28–1.31)	0.202
Baseline LVEDD	0.98 (0.94–1.02)	0.369	0.99 (0.95–1.03)	0.833
Baseline LVEDD > 60 mm	1.12 (0.32–3.94)	0.864	0.58 (0.13–2.59)	0.476
Pre-discharge LVEDD	0.98 (0.94–1.03)	0.594	0.96 (0.92–1.01)	0.127
Delta LVEDD	1.01 (0.96–1.06)	0.687	0.96 (0.91–1.01)	0.135
Baseline LVEF	0.99 (0.96–1.02)	0.809	1.00 (0.97–1.04)	0.874
Baseline LVEF < 30%	2.47 (0.87–7.06)	0.089	0.89 (0.20–4.05)	0.882
Delta LVEF	0.97 (0.92–1.03)	0.337	0.99 (0.94–1.06)	0.882
Pre-discharge LVEF	0.98 (0.96–1.02)	0.385	0.99 (0.97–1.03)	0.986
Baseline TAPSE	0.98 (0.95–1.12)	0.411	1.00 (0.95–1.06)	0.400
Baseline TAPSE < 17 mm	1.41 (0.59–3.40)	0.433	1.17 (0.42–3.28)	0.754
TAPSE/sPAP	1.00 (0.98–1.02)	0.833	1.01 (0.99–1.02)	0.220
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.65–3.21)	0.356	0.90 (0.39–2.09)	0.824
Pre-discharge TAPSE	0.97 (0.88–1.08)	0.636	0.96 (0.85–1.07)	0.466
Atrial fibrillation	1.34 (0.65–2.77)	0.427	1.07 (0.51–2.22)	0.856

Bold values denote statistical significance at the p < 0.05 level.

Abbreviations: CKD, chronic kidney disease; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; PM, pacemaker; RAAS, renin–angiotensin–aldosteron; RV, right ventricle; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annulus plane systolic excursion; T-TEER, tricuspid transcatheter edge-to-edge repair; TR, tricuspid regurgitation.

This Feature Is Available To Subscribers Only